--- title: "Beam Therapeutics | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 490 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/294812977.md" datetime: "2026-08-04T11:11:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294812977.md) - [en](https://longbridge.com/en/news/294812977.md) - [zh-HK](https://longbridge.com/zh-HK/news/294812977.md) generator: "portal-rs" --- # Beam Therapeutics | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 490 K Revenue: As of FY2026 Q2, the actual value is USD 490 K, missing the estimate of USD 17.2 M. EPS: As of FY2026 Q2, the actual value is USD -1.18, missing the estimate of USD -1.0977. EBIT: As of FY2026 Q2, the actual value is USD -126.55 M. ### Financial Position (as of June 30, 2026, compared to December 31, 2025) #### Cash, Cash Equivalents, and Marketable Securities Beam Therapeutics Inc. reported cash, cash equivalents, and marketable securities totaling $1,152,927 thousand as of June 30, 2026, a decrease from $1,245,210 thousand as of December 31, 2025. #### Total Assets Total assets were $1,386,355 thousand as of June 30, 2026, down from $1,481,177 thousand as of December 31, 2025. #### Total Liabilities Total liabilities increased to $318,913 thousand as of June 30, 2026, from $242,819 thousand as of December 31, 2025. #### Total Stockholders’ Equity Total stockholders’ equity decreased to $1,067,442 thousand as of June 30, 2026, from $1,238,358 thousand as of December 31, 2025. ### Second Quarter 2026 Financial Performance (compared to Second Quarter 2025) #### License and Collaboration Revenue License and collaboration revenue for the second quarter of 2026 was $490 thousand, a decrease from $8,466 thousand for the second quarter of 2025. #### Operating Expenses Research and Development (R&D) expenses were $95,096 thousand for the second quarter of 2026, down from $101,758 thousand for the second quarter of 2025. General and Administrative (G&A) expenses increased to $31,947 thousand for the second quarter of 2026, from $26,859 thousand for the second quarter of 2025. Total operating expenses were $127,043 thousand for the second quarter of 2026, compared to $128,617 thousand for the second quarter of 2025. #### Loss from Operations Loss from operations for the second quarter of 2026 was - $126,553 thousand, compared to - $120,151 thousand for the second quarter of 2025. #### Net Loss Beam Therapeutics Inc. reported a net loss of - $122,678 thousand for the second quarter of 2026, compared to a net loss of - $102,138 thousand for the second quarter of 2025. #### Comprehensive Loss Comprehensive loss for the second quarter of 2026 was - $123,797 thousand, compared to - $102,288 thousand for the second quarter of 2025. ### Six Months Ended June 30, 2026 Financial Performance (compared to Six Months Ended June 30, 2025) #### License and Collaboration Revenue For the six months ended June 30, 2026, license and collaboration revenue was $32,228 thousand, an increase from $15,936 thousand for the same period in 2025. #### Operating Expenses Research and Development (R&D) expenses were $199,620 thousand for the six months ended June 30, 2026, slightly down from $200,574 thousand for the same period in 2025. General and Administrative (G&A) expenses increased to $66,376 thousand for the six months ended June 30, 2026, from $54,799 thousand for the same period in 2025. Total operating expenses were $265,996 thousand for the six months ended June 30, 2026, compared to $255,373 thousand for the same period in 2025. #### Loss from Operations Loss from operations for the six months ended June 30, 2026, was - $233,768 thousand, an improvement from - $239,437 thousand for the same period in 2025. #### Net Loss Net loss for the six months ended June 30, 2026, was - $216,996 thousand, compared to - $210,468 thousand for the same period in 2025. #### Comprehensive Loss Comprehensive loss for the six months ended June 30, 2026, was - $220,296 thousand, compared to - $211,137 thousand for the same period in 2025. ### Outlook / Guidance Beam Therapeutics Inc. expects its cash, cash equivalents, and marketable securities as of June 30, 2026, combined with an anticipated $200 million draw from its facility with Sixth Street, to fund operating expenses and capital expenditure requirements into mid-2029. This funding is projected to support the anticipated launch of risto-cel in Sickle Cell Disease (SCD), the BEAM-302 pivotal development plan in Alpha-1 Antitrypsin Deficiency (AATD), and clinical proof of concept for BEAM-304 in Phenylketonuria (PKU). ### Related Stocks - [BEAM.US](https://longbridge.com/en/quote/BEAM.US.md) ## Related News & Research - [Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results](https://longbridge.com/en/news/295256769.md) - [Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary](https://longbridge.com/en/news/294814748.md) - [Beam Communications Declares Dividend for FY2026 Shareholders](https://longbridge.com/en/news/296546543.md) - [Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod](https://longbridge.com/en/news/296403735.md) - [Beam Therapeutics Inc. $BEAM Shares Acquired by Janus Henderson Group PLC](https://longbridge.com/en/news/295319641.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**